David Vetrie
Overview
Explore the profile of David Vetrie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
5132
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dawson A, Zarou M, Prasad B, Bittencourt-Silvestre J, Zerbst D, Himonas E, et al.
Nat Commun
. 2024 Feb;
15(1):1090.
PMID: 38316788
Macrophages are fundamental cells of the innate immune system that support normal haematopoiesis and play roles in both anti-cancer immunity and tumour progression. Here we use a chimeric mouse model...
2.
Scott M, Liu W, Mitchell R, Clarke C, Kinstrie R, Warren F, et al.
Nat Commun
. 2024 Jan;
15(1):651.
PMID: 38246924
Whilst it is recognised that targeting self-renewal is an effective way to functionally impair the quiescent leukaemic stem cells (LSC) that persist as residual disease in chronic myeloid leukaemia (CML),...
3.
Gomez-Castaneda E, Hopcroft L, Rogers S, Munje C, Bittencourt-Silvestre J, Copland M, et al.
Cancers (Basel)
. 2022 Nov;
14(21).
PMID: 36358672
Tyrosine kinase inhibitors (TKI) have revolutionised the treatment of CML. However, TKI do not eliminate the leukaemia stem cells (LSC), which can re-initiate the disease. Thus, finding new therapeutic targets...
4.
Lebecque B, Bourgne C, Munje C, Berger J, Tassin T, Cony-Makhoul P, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230624
RNA splicing factors are frequently altered in cancer and can act as both oncoproteins and tumour suppressors. They have been found mutated or deregulated, justifying the growing interest in the...
5.
Ianniciello A, Zarou M, Rattigan K, Scott M, Dawson A, Dunn K, et al.
Sci Transl Med
. 2021 Sep;
13(613):eabd5016.
PMID: 34586834
Inhibition of autophagy has been proposed as a potential therapy for individuals with cancer. However, current lysosomotropic autophagy inhibitors have demonstrated limited efficacy in clinical trials. Therefore, validation of novel...
6.
Massett M, Monaghan L, Patterson S, Mannion N, Bunschoten R, Hoose A, et al.
Cell Death Dis
. 2021 Jun;
12(6):573.
PMID: 34083515
Epigenomic dysregulation is a common pathological feature in human hematological malignancies. H3K9me3 emerges as an important epigenomic marker in acute myeloid leukemia (AML). Its associated methyltransferases, such as SETDB1, suppress...
7.
Vetrie D, Helgason G, Copland M
Nat Rev Cancer
. 2020 Jan;
20(3):158-173.
PMID: 31907378
For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell field. In CML, the...
8.
Bugler J, Kinstrie R, Scott M, Vetrie D
Front Cell Dev Biol
. 2019 Aug;
7:136.
PMID: 31380371
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by BCR-ABL1, an oncogenic fusion gene arising from the Philadelphia chromosome. The development of tyrosine kinase inhibitors (TKIs) to...
9.
Koschmieder S, Vetrie D
Semin Cancer Biol
. 2017 Aug;
51:180-197.
PMID: 28778403
The onset of global epigenetic changes in chromatin that drive tumor proliferation and heterogeneity is a hallmark of many forms of cancer. Identifying the epigenetic mechanisms that govern these changes...
10.
Holyoake T, Vetrie D
Blood
. 2017 Feb;
129(12):1595-1606.
PMID: 28159740
Chronic myeloid leukemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem cell (LSC) that self-renews, proliferates,...